Introduction

The Cycloph 500 mg (Cyclophosphamide) Injection is a high-dose alkylating chemotherapy agent designed for the treatment of aggressive hematologic malignancies and solid tumors, including Hodgkin’s disease, non-Hodgkin’s lymphoma, leukemia, and carcinomas of the breast, ovary, and bladder. Manufactured by Eskayef Pharmaceuticals Ltd., a leader in oncology innovation, and supplied by Onco Solution, a global provider of life-saving cancer therapies, this formulation delivers potent DNA cross-linking action to disrupt cancer cell proliferation. Ideal for patients requiring intensified regimens, Cycloph 500 mg combines clinical efficacy with rigorous safety protocols for advanced cancer management.

Key Benefits

• High-Dose Precision: 500 mg/vial for optimized dosing in bulky or refractory tumors.
• Broad-Spectrum Action: Effective against lymphomas, leukemias, myeloma, and carcinomas.
• Combination Synergy: Enhances outcomes when paired with radiotherapy or other antineoplastic agents.

Indications

The Cycloph 500 mg (Cyclophosphamide) Injection is indicated for:

• Malignant Lymphomas: Hodgkin’s disease, Burkitt’s lymphoma, histiocytic lymphoma.
• Leukemias: Chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL).
• Solid Tumors: Breast carcinoma, ovarian adenocarcinoma, neuroblastoma, retinoblastoma.
• Multiple Myeloma and Mycosis Fungoides (advanced stages).

Pharmacology

• Mechanism of Action: Cyclophosphamide is metabolized in the liver to active alkylating metabolites, which cross-link DNA strands, blocking replication and triggering apoptosis in rapidly dividing cancer cells.
• Synergy: Amplifies tumor suppression when combined with anthracyclines, vincristine, or monoclonal antibodies.

Dosage & Administration

Malignant Diseases (Adults & Pediatrics)

• Intravenous Monotherapy:
  • Initial Dose: 40–50 mg/kg divided over 2–5 days (e.g., 500 mg daily for 4 days in a 70 kg patient).
  • Alternative Regimens:
    • 10–15 mg/kg every 7–10 days.
    • 3–5 mg/kg twice weekly.
• Combination Therapy: Adjust doses when used with other cytotoxic drugs (e.g., reduce by 20–30%).

Preparation & Handling

• Reconstitution:
  • Direct IV Injection: Dilute to 20 mg/mL using 0.9% NaCl, 0.45% NaCl, or 5% dextrose.
    • Example: 500 mg vial + 25 mL diluent.
  • IV Infusion: Dilute to 2 mg/mL with the same solutions.
    • Example: 500 mg vial + 250 mL diluent.
• Administration:
  • Infuse slowly over 30–60 minutes to minimize adverse reactions (e.g., facial swelling, nasal congestion).
  • Avoid Sterile Water for Injection (risk of hypotonic hemolysis).

Storage

• Unopened Vials: Store at 25°C; protect from light.
• Reconstituted Solution:
  • Refrigerate at 2–8°C (36–46°F) for up to 28 days.
  • Discard unused portions after 28 days.

Contraindications

• Hypersensitivity to cyclophosphamide or its components.
• Urinary outflow obstruction or severe renal impairment.

Side Effects

Common Reactions:

• Hematologic: Severe neutropenia, thrombocytopenia, anemia.
• Gastrointestinal: Nausea, vomiting, diarrhea, anorexia.
• Dermatologic: Alopecia (reversible post-treatment), skin pigmentation changes.

Serious Risks:

• Myelosuppression: Life-threatening infections due to immunosuppression.
• Cardiotoxicity: Myocarditis, pericardial effusion, congestive heart failure.
• Pulmonary Toxicity: Pneumonitis, pulmonary fibrosis (monitor for dyspnea).
• Secondary Malignancies: Increased risk of bladder/hematologic cancers.

Warnings & Precautions

1. Hydration Protocol:
   • Administer 2–3 liters of IV fluid daily to prevent hemorrhagic cystitis.
   • Monitor urine output and renal function (creatinine, BUN).
2. Infection Control:
   • Prophylactic antibiotics/antivirals for immunocompromised patients.
3. Cardiac Monitoring:
   • Baseline ECG and echocardiogram for high-risk patients.
4. Fertility Preservation:
   • Offer cryopreservation options due to risk of irreversible gonadal suppression.

Adverse Reactions

• Hepatotoxicity: Veno-occlusive liver disease (fatal in severe cases).
• Neurologic: Hyponatremia, seizures (rare).
• Reproductive: Infertility, teratogenicity (Category D pregnancy risk).

Use in Specific Populations

• Pregnancy: Contraindicated. Use effective contraception during and for 1 year post-treatment.
• Lactation: Discontinue breastfeeding due to infant toxicity risks.
• Renal Impairment: Reduce dose in moderate-to-severe cases (eGFR < 30 mL/min).

Why Choose Cycloph 500 mg (Cyclophosphamide) Injection?

• High-Dose Flexibility: Ideal for patients requiring aggressive regimens or larger body surface areas.
• Trusted Manufacturer: Produced by Eskayef Pharmaceuticals Ltd., a pioneer with 30+ years in oncology innovation.
• Global Accessibility: Supplied by Onco Solution, ensuring affordable access across Asia, Africa, and Europe.

Technical Specifications

• Active Ingredient: Cyclophosphamide USP (500 mg/vial).
• Packaging: Lyophilized powder in sterile, tamper-evident vials.
• Shelf Life: 24 months (unopened).

Commitment to Excellence

Eskayef Pharmaceuticals Ltd., part of Bangladesh’s Transcom Group, merges cutting-edge research with uncompromising quality control. Partnering with Onco Solution, they bridge global healthcare gaps, delivering life-saving therapies to underserved regions with a focus on affordability and efficacy.

Conclusion

The Cycloph 500 mg (Cyclophosphamide) Injection is a cornerstone of modern oncology, offering potent DNA-targeted action for aggressive hematologic and solid tumors. By integrating this high-dose alkylating agent into treatment plans, clinicians leverage a trusted solution backed by Eskayef Pharmaceuticals Ltd. and Onco Solution – leaders in global cancer care innovation.